» Articles » PMID: 10067673

Lipopeptide Particles As the Immunologically Active Component of CTL Inducing Vaccines

Overview
Journal Vaccine
Date 1999 Mar 6
PMID 10067673
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Using a bipalmitoylated lipopeptide consisting of an ovalbumin helper T-cell epitope covalently linked to an influenza virus cytotoxic T-lymphocyte (CTL) epitope, we addressed possible factors that may be critical for CTL induction. Antigen processing of lipopeptide appears to be required for T-cell induction since there was virtually no in vitro binding of lipopeptide to purified MHC molecules. A major portion of lipopeptide immunogenicity was due to its particulate nature inasmuch as CTL induction in mice correlated with insoluble lipopeptide constructs, whereas more soluble analogs were significantly less immunogenic. Immunohistological analysis of tissue from immunized animals revealed that lipopeptide migration from the s.c. injection site to the spleen could be detected as early as 1 h after immunization and cell-associated lipopeptide was observed on macrophages and dendritic cells, implicating both cell populations in the processing and presentation of lipopeptide particles to CTLs.

Citing Articles

Critical evaluation on roles of macrophagic myofasciitis and aluminum adjuvants in HPV vaccine-induced adverse events.

Matsumura N, Shiro R, Tsunoda I Cancer Sci. 2023; 114(4):1218-1228.

PMID: 36601818 PMC: 10067403. DOI: 10.1111/cas.15714.


Peptide-based supramolecular vaccine systems.

ONeill C, Shrimali P, Clapacs Z, Files M, Rudra J Acta Biomater. 2021; 133:153-167.

PMID: 34010691 PMC: 8497425. DOI: 10.1016/j.actbio.2021.05.003.


Protective CD8 T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1/K transgenic mice.

Ma Y, Tang K, Zhang Y, Zhang C, Cheng L, Zhang F Virol J. 2020; 17(1):146.

PMID: 33028368 PMC: 7538842. DOI: 10.1186/s12985-020-01421-y.


High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation.

Gadd A, Castelletto V, Kabova E, Shankland K, Perrie Y, Hamley I Eur J Pharm Sci. 2018; 123:268-276.

PMID: 30048801 PMC: 6137072. DOI: 10.1016/j.ejps.2018.07.048.


The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides.

Schultz H, Ostergaard S, Sidney J, Lamberth K, Sette A PLoS One. 2018; 13(5):e0197407.

PMID: 29758051 PMC: 5951580. DOI: 10.1371/journal.pone.0197407.